ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy ...

NEWARK, DE / ACCESS Newswire / March 23, 2026 / According to Future Market Insights (FMI), the global self-amplifying RNA (saRNA) cancer immunotherapy platforms market is entering a high-growth phase ...

The approval of messenger RNA (mRNA) based COVID-19 vaccines marked a pivotal scientific milestone, establishing mRNA as an innovative drug modality with immense therapeutic potential. However, due to ...

It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

Immunomic Therapeutics, Inc. (ITI), a clinical-stage biotechnology company focused on developing transformative immune therapies through its proprietary UNITE® platform, announced today that the ...

Researchers from the Access to Advanced Health Institute and collaborating institutions have developed a promising new bivalent vaccine candidate that can protect against both yellow fever and Zika ...

Ribonucleic acid, also called RNA, is a molecule present in all living cells. It plays a critical role in transmitting genetic instructions from DNA and creating proteins. With the power to execute a ...